Eliminating residual iPS cells for safety in clinical application

Shigeo Masuda, Shigeru Miyagawa, Satsuki Fukushima, Nagako Sougawa, Kaori Okimoto, Chika Tada, Atsuhiro Saito, Yoshiki Sawa

PDF(316 KB)
PDF(316 KB)
Protein Cell ›› 2015, Vol. 6 ›› Issue (7) : 469-471. DOI: 10.1007/s13238-015-0170-4
NEWS AND VIEWS

Eliminating residual iPS cells for safety in clinical application

Author information +
History +

Cite this article

Download citation ▾
Shigeo Masuda, Shigeru Miyagawa, Satsuki Fukushima, Nagako Sougawa, Kaori Okimoto, Chika Tada, Atsuhiro Saito, Yoshiki Sawa. Eliminating residual iPS cells for safety in clinical application. Protein Cell, 2015, 6(7): 469‒471 https://doi.org/10.1007/s13238-015-0170-4

References

[1]
Huskey NE (2015) CDK1 inhibition targets the p53-NOXAMCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation. Stem Cell Rep4: 374-389
CrossRef Google scholar
[2]
Masuda S (2014) Emerging innovation towards safety in the clinical application of ESCs and iPSCs. Nat Rev Cardiol11: 553-554
CrossRef Google scholar
[3]
Tateno H (2011) Glycome diagnosis of human induced pluripotent stem cells using lectin microarray. J Biol Chem286: 20345-20353
CrossRef Google scholar
[4]
Tateno H (2015) Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion protein. Stem Cell Rep.
CrossRef Google scholar
[5]
Wu T, Pinto HB, Kamikawa YF, Donohoe ME (2015) The BET family member BRD4 interacts with OCT4 and regulates pluripotency gene expression. Stem Cell Rep4: 390-403
CrossRef Google scholar

RIGHTS & PERMISSIONS

2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
AI Summary AI Mindmap
PDF(316 KB)

Accesses

Citations

Detail

Sections
Recommended

/